SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in G12C NSCLC.
1/5 보강
www.clinicaltrials.gov identifier is NCT06119581.
APA
Peters S, Hochmair M, et al. (2026). SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in G12C NSCLC.. Future oncology (London, England), 22(9), 1073-1082. https://doi.org/10.1080/14796694.2026.2651961
MLA
Peters S, et al.. "SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in G12C NSCLC.." Future oncology (London, England), vol. 22, no. 9, 2026, pp. 1073-1082.
PMID
41940628
Abstract
www.clinicaltrials.gov identifier is NCT06119581. EudraCT: 2023-503412-33-00.
🏷️ 키워드 / MeSH
- Humans
- Carcinoma
- Non-Small-Cell Lung
- Antibodies
- Monoclonal
- Humanized
- Lung Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Proto-Oncogene Proteins p21(ras)
- Mutation
- Treatment Outcome
- Randomized Controlled Trials as Topic
- KRAS
- NSCLC
- Study design
- first-line treatment
- olomorasib
- pembrolizumab
- phase III trial
- treatment rationale
같은 제1저자의 인용 많은 논문 (5)
- First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.
- An Unusual Case of Anti-FGFR3 Antibodies, Sensory Neuropathy, and Adie Pupil in a Patient With Hodgkin Lymphoma in Remission and Review of the Literature.
- Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study.
- Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.
- Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study.